Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01148420 · ClinicalTrials.gov registry record · Phase 4
DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
A Phase 4 study of Dysfunctional Uterine Bleeding, sponsored by Women's Health Care Clinic, Torrance, California.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01148420 is a Phase 4 study of Dysfunctional Uterine Bleeding that has completed, run by Women's Health Care Clinic, Torrance, California. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01148420, a Phase 4 study of Dysfunctional Uterine Bleeding, has completed, sponsored by Women's Health Care Clinic, Torrance, California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy, prolonged uterine bleeding who have been identified as being eligible for outpatient management
Conditions Studied
Interventions
- DRUG Medroxyprogesterone 17-Acetate
- DRUG medroxyprogesterone acetate
Study Locations (1)
California
- Harbor-UCLA Urgent Care - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01148420
The ClinicalTrials.gov registry entry for NCT01148420 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women's Health Care Clinic, Torrance, California, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dysfunctional Uterine Bleeding appearing as the primary indexed condition, and to 2 interventions - of which Medroxyprogesterone 17-Acetate is the first listed.
NCT01148420 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01148420 about?
NCT01148420 is a clinical study titled "DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding". The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy, prolonged uterine bleeding who have been identified as being eligible for o...
What is the current status of trial NCT01148420?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2009-01. Estimated completion is 2012-07.
What conditions does trial NCT01148420 study?
This clinical trial studies the following conditions: Dysfunctional Uterine Bleeding.
What interventions are being tested in trial NCT01148420?
The interventions under investigation include: Medroxyprogesterone 17-Acetate (DRUG), medroxyprogesterone acetate (DRUG).
Who is sponsoring clinical trial NCT01148420?
This trial is sponsored by Women's Health Care Clinic, Torrance, California, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01148420 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.